{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of [99m Tc]Tilmanocept for Sentinel Lymph Node Mapping in Breast Cancer"
      },
      "Trial_Design": {
        "score": 0,
        "evidence": "The study was nonrandomized, and all patients received both interventions."
      },
      "Participants": {
        "score": 2,
        "evidence": "Conducted at 13 centers, 148 breast cancer patients without presurgical lymph node metastases were enrolled."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Each received [99m Tc]tilmanocept and vital blue dye (VBD)."
      },
      "Objective": {
        "score": 1,
        "evidence": "This study assesses [99m Tc]tilmanocept, a novel receptor-targeted radiopharmaceutical, in SLN mapping."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the concordance of SLN detection between [99m Tc]tilmanocept and VBD, measured intraoperatively."
      },
      "Randomisation_Allocation": {
        "score": 0,
        "evidence": "The study was nonrandomized, and all patients received both interventions."
      },
      "Blinding": {
        "score": 0,
        "evidence": "Not reported"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "148 breast cancer patients without presurgical lymph node metastases were enrolled."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "Of 148 patients, 207 of 209 nodes detected by VBD were also detected by [99m Tc]tilmanocept."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "achieving a concordance rate of 99.04% (p < 0.0001)"
      },
      "Harms": {
        "score": 1,
        "evidence": "No serious adverse events were attributed to [99m Tc]tilmanocept. Adverse events were mild and included nausea and seroma."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT00671918 and NCT01106040."
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: Sponsored by Navidea Biopharmaceuticals."
      }
    },
    "total_score": 16,
    "max_score": 25
  },
  "model": "gpt-4o"
}